Status:
UNKNOWN
Beta-lactam Therapeutic Drug Monitoring in Singapore
Lead Sponsor:
Singapore General Hospital
Conditions:
Infection, Bacterial
Eligibility:
All Genders
21-99 years
Brief Summary
This is a prospective cohort study to evaluate clinical utility and feasibility of beta-lactam therapeutic drug monitoring in Singapore. The investigators hypothesise that conventional beta-lactam dos...
Detailed Description
Despite widespread use, conventional beta-lactam dosing regimens, derived from healthy volunteers, are sub-optimal clinically as patients display variable pharmacokinetics. This problem is further con...
Eligibility Criteria
Inclusion
- Adult patients (21 years and above)
- Admitted to Singapore General Hospital
- Receiving beta-lactam therapy for documented or suspected infection
- Indication for beta-lactam therapeutic drug monitoring: critically ill, altered pharmacokinetics (burns, obese, on extracorporeal therapy, dialysis), immunocompromised, resistant pathogens, deep-seated infections, suspected or at risk for adverse effects
Exclusion
- Expected mortality within next 24 hours
- Pregnancy
Key Trial Info
Start Date :
October 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04450680
Start Date
October 10 2019
End Date
June 1 2022
Last Update
April 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore General Hospital
Singapore, Singapore